Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — Corporate Update (June 2025)
19 slides from Jasper Therapeutics's corporate update, Jun 16, 2025
Slide 1: Jasper Therapeutics SPOTLIGHT Data Update June 16, 2025
Jasper Therapeutics SPOTLIGHT Data Update June 16, 2025
Slide 2: Safe Harbor Statements
2 B RIQU ILIMAB IS AN INVES TIGATIVE DRU G AND IS NOT APPROVED FOR ANY INDICATION Safe Harbor Statements Forward - Looking Statements Certain statements in this Presentation include “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
Slide 3: Today's Agenda
B RIQU ILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION 3 Today’s Agenda • Opening Remarks • SPOTLIGHT 180mg Results Summary • Upcoming Milestones and Closing Remarks • Question & Answer Session
Slide 4: SPOTLIGHT 180mg Results Summary
SPOTLIGHT 180mg Results Summary
Slide 5: CIndU can be a severe and debilitating disease with negative impacts on quality of life
5 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION CIndU can be a severe & debilitating disease with negative impacts on quality of life for patients • Chronic inducible urticaria (CIndU) is a debilitating inflammatory condition of the skin with a specific trigger such as
Slide 6: SPOTLIGHT study design
Screening/Eligibility • Diagnosis of Cold Urticaria (ColdU) or Symptomatic Dermographism (SD) for ≥ 3 mos • H1 - antihistamine - failed • 18+ years • 18 - 65 years of age Study Operations • EU Lead: Martin Metz, MD • ~5 sites in the EU • N = ~27 Key Assessments • Provocation Test: TempTest ® (ColdU)
Slide 7: Rapid Onset of Deep and Durable Efficacy Observed at 180mg Dose
Rapid Onset of Deep and Durable Efficacy Observed at 180mg Dose 7 B RIQU ILIMAB IS AN INVES TIGATIVE DRU G AND IS NOT APPROVED FOR ANY INDICATION Depth of Response • 12 of 12 patients (100%) at 180mg achieved clinical response following single - dose of briquilimab • 11 of 12 patients (92%) at 180mg
Slide 8: SPOTLIGHT Baseline Demographics
SPOTLIGHT Baseline Demographics Briquilimab 180mg Briquilimab 120mg Briquilimab 40mg (n=12) (n=12) (n=3) 39.9 (16.0) 46.4 (13.8) 35.3 (8.0) Age (years), mean (SD) 7 (58%) 8 (67%) 1 (33%) Female, n (%) 86.5 (54 - 104) 99.0 (57 - 115) 86.0 (69 - 94) Weight (kg), median (range) 3 4 1 Cold Urticaria, n
Slide 9: SPOTLIGHT: Dose dependent reductions in serum tryptase
* All values below LLOQ (1.0 µg/L) are represented as 0 µg/L 9 B RIQU ILIMAB IS AN INVES TIGATIVE DRU G AND IS NOT APPROVED FOR ANY INDICATION SPOTLIGHT: Dose dependent reductions in serum tryptase Reduction to below Lower Limit of Quantification (LLOQ) (1 µg/L) seen in 83.3% (10/12) participants at
Slide 10: SPOTLIGHT Efficacy Evaluation
SPOTLIGHT Efficacy Evaluation Briquilimab 180mg single dose achieved 92% (11 of 12) CR by week 8 Briquilimab 40mg (n=3) Briquilimab 120mg (n=12) Briquilimab 180mg (n=12) Briquilimab All doses (n=27) Complete Response, n (%) 1 (33%) 10 (83.3%) 11 (92%) 22 (82%) ColdU, n 0 3 3 6 Symptomatic Dermograph
Slide 11: Clinical response through weeks with briquilimab 180mg
SPOTLIGHT: Clinical response through 8 weeks with briquilimab 180mg (n=12) AD_T0003, AD_T0004, AD_L0001, AD_L0002 • 12 of 12 patients (100%) achieved either CR or PR by week 8 • 8 of 12 patients (67%) achieved clinical response by the week 2 assessment • 11 of 12 participants (92%) reported either C
Slide 12: Clear Dose Response Demonstrated at Weeks Post-Dose
Clear Dose Response Demonstrated at 6 Weeks Post - Dose 75% CRs at 180mg dose improved on 50% CRs observed at 120mg Briquilimab 40mg (n=3) Briquilimab 120mg (n=12) Briquilimab 180mg (n=12) Complete Response, n (%) 0 (0%) 6 (50%) 9 (75%) ColdU, n 0 1 3 Symptomatic Dermographism, n 0 5 6 Partial Respo
Slide 13: SPOTLIGHT Safety and Tolerability
SPOTLIGHT Safety and Tolerability Briquilimab 40mg (n=3) Briquilimab 120mg (n=12) Briquilimab 180mg (n=12) Any adverse event 2 12 10 Any serious adverse event 0 2* 0 Any adverse event leading to discontinuation 0 0 0 Adverse event leading to death 0 0 0 0 Adverse event ≥ grade 3 0 1* *SAE: Biliary c
Slide 14: Safety/Tolerability Observations Possibly Related to KIT Blockade
SPOTLIGHT Safety/Tolerability Observations Possibly Related to KIT Blockade Were Generally Limited to Low Grade Events All events were grade 1 or 2 and none resulted in discontinuations Adverse Event as reported term Briquilimab 40mg (n=3) n (%) Briquilimab 120mg (n=12) n (%) Briquilimab 180mg (n=12
Slide 15: SPOTLIGHT Absolute Neutrophil Count
SPOTLIGHT Absolute Neutrophil Count Neutrophil counts generally remained stable, with predictable reductions which subsequently resolved 15 B RIQU ILIMAB IS AN INVES TIGATIVE DRU G AND IS NOT APPROVED FOR ANY INDICATION
Slide 16: Upcoming Milestones and Closing Remarks
Upcoming Milestones and Closing Remarks
Slide 17: Takeaways
Takeaways 17 B RIQU ILIMAB IS AN INVES TIGATIVE DRU G AND IS NOT APPROVED FOR ANY INDICATION • Single 180mg dose of briquilimab demonstrated 100% clinical response in participants with CIndU • Deep reduction of tryptase observed with 83% of participants below LLOQ in 180 mg cohort • Rapid onset of s
Slide 18: Key milestones
Key milestones = Completed = Future events/milestones 2 02 4 CSU CIndU Asthma Conferences 2 02 5 2 02 6 Registrational Phase 1b/2a Initial clinical data OLE Study Phase 1b/2a OLE E Study Clinical data all patients Next Mast Cell Indication Initial clinical data Phase 1b/2a First patient dosed Initia
Slide 19: Jasper Therapeutics SPOTLIGHT Data Update June 16, 2025
Jasper Therapeutics SPOTLIGHT Data Update June 16, 2025